# To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation

> **NCT00189319** · PHASE4 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 200 (—)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Flecainide controlled release

## Key facts

- **NCT ID:** NCT00189319
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 200 (—)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189319, "To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00189319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*